These antibodies efficiently stop the seeding and propagation of AD-derived tau, whereas antibodies against the N-term inhibit seeding only very weakly (39), emphasizing the importance of selecting the right epitopes to achieve therapeutic effects. The gene discussed is MAPT; the disease is Alzheimer disease.